Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study
Open Access
- 8 October 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R37CA229221)
- National Institutes of Health (P30CA118100)
- V Foundation for Cancer Research (T2023-004)
- AstraZeneca (INST1419)
This publication has 54 references indexed in Scilit:
- A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancerInternational Journal of Gynecological Cancer, 2025
- PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOT-OV65/KEYNOTE-B96 STUDYInternational Journal of Gynecological Cancer, 2025
- PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian CancerJAMA Network Open, 2025
- The emerging roles of IFIT3 in antiviral innate immunity and cellular biologyJournal of Medical Virology, 2022
- VSTM5 is a novel immune checkpoint that promotes oral tolerance of cell-mediated and antibody responsesBiochemical and Biophysical Research Communications, 2022
- Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STINGCell Reports, 2021
- FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian CancerThe Oncologist, 2020
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaJAMA Oncology, 2019
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 TherapyCell, 2016
- Intraepithelial T cells and tumor proliferationCancer, 2009